Home › Funds › NEXTBio Capital Management LP › XENE
NEXTBio Capital Management LP position in XENE
XENON PHARMACEUTICALS INC · Health Care
NEXTBio Capital Management LP reported holding 310,225 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.5M, representing 5.02% of its reported portfolio and ranking #7 among its reported holdings. NEXTBio Capital Management LP has disclosed XENE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's XENE position evolved
NEXTBio Capital Management LP first disclosed a stake in XENE in Q4 2025 at 183,704 shares (US$8.2M). The position peaked in Q3 2026 at 310,225 shares, worth US$11.5M. Across 4 filings, NEXTBio Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 310,225 shares valued at US$11.5M — an increase of 127,000 shares quarter over quarter.. Notable position changes include a 69% increase in Q3 2026 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 183.70K | $8.23M | New |
| Q1 2026 | 183.22K | $10.65M | Hold |
| Q2 2026 | 183.22K | $11.06M | Hold |
| Q3 2026 | 310.23K | $11.54M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.78M sh · $348.75M · Q2 2026
- Polar Capital Holdings Plc 4.57M sh · $275.88M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.42M sh · $266.70M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.59M sh · $96.27M · Q2 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Caption Management, LLC 728.00K sh · $43.94M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
- Rock Springs Capital Management LP 683.91K sh · $41.28M · Q2 2026
- First Turn Management, LLC 600.20K sh · $36.23M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held XENE?
NEXTBio Capital Management LP has disclosed XENE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in XENE?
As of Q3 2026, NEXTBio Capital Management LP holds 310.23K shares of XENE (XENON PHARMACEUTICALS INC), valued at $11.54M, representing 5.02% of its reported portfolio and ranking #7.
Has NEXTBio Capital Management LP been buying or selling XENE?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP increased its position in XENE. The position peaked in Q3 2026 at 310.23K shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.